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Human b-Defensin-1 Is a Salt-Sensitive
Antibiotic in Lung That Is Inactivated
in Cystic Fibrosis
Mitchell J. Goldman,* G. Mark Anderson,† Smith et al. (1996) recently presented data that sup-
port a defect in host defense in the CF lung. UsingEthan D. Stolzenberg,† U. Prasad Kari,†
primary cultures of human airway epithelial cells, theyMichael Zasloff,† and James M. Wilson*
showed that the airway surface fluid (ASF) from normal*Department of Medicine
respiratory epithelia was capable of killing pathogensDepartment of Molecular and Cellular
such as P. aeruginosa, whereas the ASF from CF cellsEngineering
was not. Diluting normal ASF into hypertonic solutionThe Institute for Human Gene Therapy
eliminated antibacterial activity, while diluting CF ASFThe University of Pennsylvania Medical Center
with hypotonic solutions increased this activity. ThisThe Wistar Institute
suggested that an antibacterial substance is present inPhiladelphia, Pennsylvania 19104
ASF that is reversibly inactivated in the high salt milieu†The Magainin Research Institute
of CF. They proposed a model whereby the defect inMagainin Pharmaceuticals Inc.
the CF gene product, the cystic fibrosis transmembranePlymouth Meeting, Pennsylvania 19462
conductance regulator (CFTR), leads to elevated NaCl
in ASF, which inactivates antimicrobial molecules. This
model would resemble the absorptive epithelia of sweatSummary
glands that result in elevated levels of Na and Cl in
sweat when CFTR is deficient (Quinton, 1983). DirectA human bronchial xenograft model was used to char-
measurements of the ionic composition of human ASFacterize the molecular basis for the previously de-
support this hypothesis. Gilljam et al. (1989) showed anscribed defect in bacterial killing that is present in the
increase in Cl from bronchial secretions from 85 6 54cystic fibrosis (CF) lung. Airway surface fluid from CF
mM in non-CF to 170 6 79 mM in CF. Joris et al. (1993)grafts contained abnormally high NaCl and failed to kill
measured Na and Cl concentration from non-CF tra-bacteria, defects that were corrected with adenoviral
cheal ASF to be 82 6 6 mM and 84 6 9 mM, respectively,vectors. A full-length clone for the only known human
which increased to 121 6 4 mM and 129 6 5 mM in CF.
b-defensin (i.e., hBD-1) was isolated. This gene is ex-
The nature of these salt-sensitive bactericidal moleculespressed throughout the respiratory epithelia of non-
in ASF was not described by Smith et al. (1996).CF and CF lungs, and its protein product shows salt-
In evaluating the biology of the antimicrobial activitydependent antimicrobial activity to P. aeruginosa.
normally present in ASF, a variety of molecules shouldAntisense oligonucleotides to hBD-1 ablated the anti-
be considered, including inorganic molecules (e.g. hy-
microbial activity in airway surface fluid from non-
drogen peroxide and nitric oxide), enzymes (e.g. prote-
CF grafts. These data suggest that hBD-1 plays an
ases and neuraminidases), and cytotoxic peptides, suchimportant role in innate immunity that is compromised
as the antimicrobial peptides called defensins. This fam-in CF by its salt-dependent inactivation.
ily of small structurally similar peptides contributes to
innate immunity in a wide variety of invertebrate and
Introduction vertebrate organisms (Ganz and Lehrer, 1994, 1995). The
a-defensins, which are found exclusively in mammals
Study of the primary molecular and cellular defects re- (including humans), play a major role in host defense
sponsible for cystic fibrosis (CF) lung disease has been at multiple sites, with the highest expression noted in
complicated by the secondary abnormalities that result neutrophil granules and Paneth cells of the gut. b-defen-
from chronic respiratory infections. One hypothesis is sins have been described in a broader array of organ-
that ion transport abnormalities in the respiratory-con- isms and sites.
ducting epithelia lead todehydration of mucus, inspissa- Zasloff and colleagues isolated the only known airway
tion of secretions, and diminished clearance of inhaled epithelial defensins, tracheal antimicrobial peptide (TAP)
pathogens (Welsh et al., 1995). Another model is that and lingual antimicrobial peptide (LAP), which are mem-
the macromolecular composition of mucus in the CF bers of the b-defensin family. TAP was purified from
airway is abnormal, affecting both its rheologic proper- cow trachea and shown to have bactericidal activity
ties and affinity for microorganisms (Cheng et al., 1989; against a broad array of organisms (Diamond et al.,
Tang et al., 1995; Pier et al., 1996). A more recent hypoth- 1991). It is expressed at high levels in columnar epithelia
esis suggests the primary event in pathogenesis is colo- of the proximal conducting airway. A similar but distinct
nization of the airway with pathogenic bacteria that initi- molecule called LAP was isolated from cow tongue
ate cycles of infection, inflammation, airway obstruction, (Schonwetter et al., 1995). Genes encoding these pep-
and destruction of lung architecture. In this model, mu- tides are upregulated at a transcriptional level in re-
cus represents the debris of chronic inflammation and sponse to bacterial LPS and inflammatory cytokines
cell destruction composed of cellular DNA and cytoskel- such as TNFa (Diamond et al., 1996; Russell et al., 1996).
etal proteins. Recent studies of CF infants who under- Activation of LAP expression is observed in vivo at ac-
went bronchoscopy in the first months of life revealed tual sites of inflammation. These two molecules are not
evidence of inflammation and bacterial colonization be- stored in intracellular granules, which clearly distin-
fore onset of clinically overt disease (Armstrong et al., guishes them from known a-defensins.
The goal of this study was to define the molecular1995, 1996).
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basis of the antimicrobial activity in human ASF that is
defective in CF.
Results
A Salt-Sensitive Bactericidal Activity Exists
in ASF of Human Xenografts
To evaluate further the molecular basis of the defect in
bacterial killing in CF ASF, we used an authentic model
for CF lung biology based on the growth of human bron-
chial xenografts in nu/nu mice (Engelhardt et al., 1992b,
1993a; Goldman et al., 1995; Zhang et al., 1996). Primary
cultures of epithelial cells derived from the proximal
airways of CF and non-CF patients were seeded into
denuded rat trachea and implanted subcutaneously into
nu/nu mice with the proximal and distal ends open to
the surface via ligated tubing. Within two weeks, a pseu-
dostratified epithelium of human origin was established.
Quantitative morphometric analysis of transmission
electron micrographs indicated that the epithelium gen-
erated on the xenograft was indistinguishable in organi-
zation, cell type distribution, and ultrastructure when
compared to the epithelium of the native bronchus from
which the epithelial cells were derived (Engelhardt et al.,
1992b, 1993a; Zhang et al., 1996). Submucosal glands
containing ducts with serous and mucus tubules are
partially formed (Engelhardt et al., 1995). Previous stud-
ies evaluated the ion-conductive properties of the xeno-
graft epithelia through the measurement of surface volt-
age in response to modulators of ion transport. In these
studies, we showed functional properties of these epi-
thelia were identical to those observed in the human
nasal and intrapulmonary airways (Goldman et al., 1995).
The most discriminating measurement between non-CF
Figure 1. Correction of the CF Defect in Xenografts Normalizes ASF
and CF was the change in voltage measured in response Salt Concentration and Restores Its Bactericidal Activity
to a decrease in luminal Cl and activation with cAMP. ASF was collected from non-CF (left), CF (middle), and CF bronchial
A number of xenografts were established for charac- xenografts treated with a recombinant adenovirus expressing CFTR
terization of the antimicrobial defect in ASF, including (right). In this fluid, sodium (open inverted triangle) and chloride
(closed inverted triangle) concentrations were measured and anti-12 grafts from 6 non-CF patients and 12 grafts from 3
bacterial liquid broth assays performed against 103 CFU of P. aerugi-CF patients. Results of the studies are presented in
nosa (middle and bottom rows, respectively). Each point shownFigure 1. Non-CF grafts were distinguished from CF
represents results from an individual graft (n 5 12). Transepithelial
grafts based on the measure of DVT in response to low potential difference measurements were obtained from xenografts
chloride and cAMP (non-CF: 214.3 6 1.1 mV; CF: 20.3 6 before and after gene transfer. The data presented (top row) show
0.3 mV). ASF from xenografts was obtained for antimi- the change in transepithelialpotential difference in amiloride-treated
epithelium in response to both chloride substitution and cAMPcrobial assays and ion measurements by expelling the
agonist treatment. As controls, non-CF (n 5 6) and CF xenograftsluminal contents with air, followed by a brief centrifuga-
(n 5 6) were treated with a recombinant adenovirus expressingtion to remove mucus. Direct ionic measurements of
b-galactosidase. The ion measurements and antibacterial proper-
non-CF ASF revealed both the Na and Cl concentrations ties of ASF from grafts treated with the b-galactosidase vector were
to be 83 6 3 mM. Antimicrobial activity was measured similar to untreated controls (data not shown).
by incubating ASF (30 ml) with 103 P. aeruginosa for 2
hr at 378C prior to a quantitative assessment of bacterial
viability using standard colony counts. ASF from all non- The relationship between ionic composition and bac-
tericidal properties of ASF and the epithelial expressionCF xenografts completely killed bacteria. This bacterial
activity was inactivated in high salt and reducing agents, of CFTR was further studied in CF xenografts treated
with adenoviral vectors containing a cDNA encodingand fractionated through gel filtration with an apparent
molecular weight less than 10 (data not shown). Similar CFTR. E1-deleted adenoviral vectors expressing CFTR
or b-galactosidase were instilled into the lumen of CFstudies performed in CF xenografts revealed a signifi-
cant increase in Na and Cl content in ASF to 178 6 9 xenografts. In situ hybridization revealed transduction
and high-level recombinant CFTR expression in 9%–mM and 172 6 9 mM, respectively. ASF from all CF
xenografts failed to kill P. aeruginosa. Diluting CF ASF in 15% of surface epithelial cells (Figure 2). CFTR gene
transfer corrected the conductive properties of the CFhypotonic solution reconstituted the bactericidal activity
(data not shown). epithelia (DVT 5 212.7 6 0.3 in response to low chloride
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Figure 2. Analysis of CF Xenografts for Ex-
pression of Recombinant mRNA Encoding
CFTR
Gene transfer to CF bronchial xenografts
treated with a recombinant adenovirus ex-
pressing CFTR was analyzed by in situ hy-
bridization. Antisense- (B and E) and sense-
(C and F) probed sections of xenograft
tissues were exposed to photoemulsion for
one week. Bright-field (A and D) and dark-
field (B and E) photomicrographs of the same
section are shown. The efficiency of gene
transfer was determined by dividing the num-
ber of positive signals by the total number
of cells present in multiple sections from an
individual graft. Magnification: (A–C) 43;
(D–F) 153.
and cAMP) and normalized ASF Na (89 6 5 mM) and Cl signals, confirming the specificity of the assay (Figure
4, right column).(87 6 4 mM) (see Figure 1). ASF from the CFTR-corrected
CF xenografts was capable of complete killing of P. To test the hypothesis that hBD-1 is a salt-sensitive
antibiotic, a synthetic form of the mature peptide wasaeruginosa in 10 out of 12 grafts, with partial killing in
the remaining 2 (Figure 1). CF xenografts treated with made, retaining the three disulfide bridges (i.e., Cys5–
Cys34, Cys12–Cys27, and Cys17–Cys35). In the presence ofsimilar doses of LacZ virus were indistinguishable from
untreated grafts (data not shown). low NaCl, synthetic hBD-1demonstrated potent bacteri-
cidal activity to a broad array of organisms, including
P. aeruginosa and E. coli (Figure 5 and data not shown).Human b-Defensin-1 Is a Salt-Sensitive
Antibiotic Expressed in Human Airway The impact of NaCl concentration on hBD-1 was evalu-
ated by incubating the synthetic peptide with 5 3 104Previous studies by Bensch et al. (1995) identified a
peptide in hemofiltrate of patients with end-stage renal colony-forming units of P. aeruginosa in the presence
of varying NaCl concentrations (Figure 5). The antimicro-disease that has structural similarities to previously de-
scribed b-defensin peptides of other organisms. A par- bial activity of hBD-1 exhibits a dramatic salt depen-
dence characterized by a sharp loss of activity as thetial cDNA for this peptide was identified from mRNA
isolated from kidney. Based on these modest sequence salt concentration increases from 50 mM to 125 mM.
Bacterial killing was observed in low salt with concentra-homologies, they named the peptide human b-defen-
sin-1 (hBD-1). tions of hBD-1 varying between 60–500 mg/ml. This titra-
tion of hBD-1 activity occurs in the range of NaCl thatWe cloned the full-length cDNA encoding hBD-1 from
mRNA derived from cultured human bronchial epithelial distinguishes non-CF from CF ASF in native human
proximal lung and the bronchial xenograft model.primary cells (Figure 3). This cDNA encodes an open
reading frame of 68 amino acids in length with the char-
acteristic features of a b-defensin, including a prepro- Antisense Inhibition of hBD-1 in Non-CF Bronchial
Xenografts Ablates Antimicrobialpeptide and six appropriately spaced cysteines. hBD-1
shows homology with the two previously described epi- Activity in ASF
Important to an understanding of CF lung pathogenesisthelial defensins from cow, i.e., TAP and LAP (Diamond
et al., 1991; Schonwetter et al., 1995). is an identification of a molecule in ASF that confers
microbial killing in non-CF lung and is inactive in CF.The homology of hBD-1 to TAP and its cloning from
mRNA of a human airway cell-line suggested it may play The tissue distribution of hBD-1 expression and its salt-
sensitivity to bacterial killing suggested it may play aa role in host defenses within human lung. Expression
of hBD-1 was evaluated in tissue from human lung by role in ASF-mediated host defense. In situ hybridization
demonstrated high-level and diffuse hBD-1 expressionin situ hybridization. Figure 4 presents a series of micro-
graphs of non-CF and CF lung tissues hybridized to in epithelia from both non-CF (Figures 4M–4O) and CF
(Figures 4P–4R) xenografts that was indistinguishableantisense and sense probes of hBD-1. High-level RNA
for hBD-1 was present throughout the superficial con- from native tissue. The role of hBD-1 in microbial killing
was further studied by genetically ablating its expres-ducting airway of non-CF lung from proximal bronchi
(Figures 4A–4C) through distal bronchioles (Figures 4D– sion with a 21-mer phosphorothioate oligonucleotide
antisense DNA specific to the 59 region of mRNA that4F). Expression was also detected throughout the epi-
thelia of submucosal glands (Figures 4A and 4B) and encodes hBD-1. Controls included 1 nonsense oligonu-
cleotide containing a scrambled sequence and 2 mis-alveolar cells (Figures 4D and 4E). This differs from the
expression of TAP in bovine lung that was primarily matched oligonucleotides identical to the antisense
oligo at 19 of 21 (mismatch 1) and 14 of 21 (mismatchdetected in proximal airway (Diamond et al., 1991). A
similar distribution of hBD-1 expression was demon- 2) nucleotides. The oligonucleotides were instilled into
the lumen of non-CF xenografts, and three days laterstrated in the CF lung (proximal airway, Figures 4G–4I;
distal airway, Figures 4J–4L). Hybridization of serial sec- ASF was harvested for microbial killing assays (Figure
6A) prior to removal of the xenografts for isolation oftions with thesense probe failed to demonstrate specific
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Figure 3. cDNA and Peptide Sequences of
hBD-1
(A) Complementary DNA and deduced amino
acid sequences of hBD-1. The double under-
line indicates a putative signal sequence; the
solid underline indicates a mature peptide;
the dash represents the termination codon;
and the bold underline marks the polyadenyl-
ation signal.
(B) Putative prepropeptide sequences of
hBD-1 and tracheal antimicrobial peptide
(TAP) are shown, along with their homology.
RNA for RT-PCR analysis of hBD-1 expression (Figure other nonhuman b-defensins (Bensch et al., 1995). Anal-
ysis of synthetic hBD-1 in our study confirmed that it6B). RNA for hBD-1 was detected by RT-PCR at equiva-
lent levels in all non-CF xenografts that were either un- has broad-spectrum antimicrobial activity against gram-
negative organisms (i.e., P. aeruginosa and E. coli) attreated or preincubated with nonsense, mismatch 1, or
mismatch 2 oligonucleotides. Preincubation of non-CF concentrations similar to what has been described for
most classical defensins (i.e., 10–100 mg/ml; Ganz andxenografts with these control nucleotides had no effect
on the ASF antimicrobial activity; eight out of nine ASF Lehrer, 1994). hBD-1 showed structural homology with
the bovine b-defensin TAP, although its distribution ofsamples completely killed bacteria while one sample
yielded only 20 colonies. Preincubation of non-CF xeno- expression within human lung is different (Diamond et
al., 1991). The gene encoding hBD-1 is diffusely ex-grafts with the hBD-1 antisense oligonucleotide sub-
stantially diminished RNA for hBD-1 in six out of eight pressed at high levels throughout the conducting and
respiratory airway from the mainstem bronchus to alve-xenografts, each of which failed to completely kill bacte-
ria; full antimicrobial activity was retained in two anti- oli, including the epithelia of the submucosal glands,
whereas expression of the TAP gene is restricted tosense-treated xenografts that were the same grafts in
which the RNA for hBD-1 was not decreased. proximal superficial epithelia.
Several observations support the hypothesis that
hBD-1 is involved in innate immunity in the lung andDiscussion
that its activity is compromised in CF. The gene encod-
ing hBD-1 is expressed at high levels in most surfaceChronic respiratory infections with pathogens such as
P. aeruginosa and S. aureus characterize the pulmonary epithelial cells throughout the lung. Secretion of hBD-1
into the airway lumen would lead to wide distributionmanifestations of CF (Welsh et al., 1995). One expla-
nation for this aspect of the disease was recently of highly concentrated antibiotic peptide in ASF, the
volume of distribution of which has been estimated tosuggested by Smith et al. (1996), who demonstrated a
salt-sensitive antimicrobial activity in the ASF of non- be no greater than 8–10 ml spread over 2 m2 of airway
surface (Boucher, 1994). In addition, the impact of NaClCF-cultured cells that was defective in CF. We describe
in this study the characterization of a novel antimicrobial on hBD-1 function correlates with the NaCl-dependent
antimicrobial activity in ASF measured by Smith et al.peptide, called human b-defensin-1 (hBD-1), which is
expressed in human airway epithelial cells and confers (1996) and in our xenograft model. Furthermore, the
change in NaCl that occurs in ASF of native lung as asalt-dependent antimicrobial activity in ASF.
hBD-1, isolated from hemodialysate of humans with result of CFTR deficiency (i.e., 80 mM NaCl in non-CF
versus 120–170 mM in CF [Gilljam et al., 1989; Joris etend-stage renal failure, was classified as a b-defensin
antimicrobial peptide based on sequence homology to al.,1993]) spans the range of NaCl that inactivates hBD-1
Human b-Defensin-1 in CF Lung Disease
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Figure 5. The Activity of hBD-1 Peptide Is Salt Dependent
Synthetic hBD-1 was incubated with 5 3 104 colony-forming units
of P.aeruginosa in 100 ml of 10 mM phosphate buffer (pH 7.4) and the
indicated concentrations of NaCl. Reactions were then incubated at
378C for 20 min. Serial dilutions were plated and colony counts
performed the following day. Similar bacterial killing in low NaCl
solution was observed with hBD-1 concentrations ranging from 60
to 500 mg/ml.
Our data suggest that the bactericidal activity in hu-
man airway to some gram-negative organisms is primar-
ily constituted through the action of a single antimicro-
bial peptide, hBD-1. This is interesting in that many
defensins exist as families of genes whose products
serve complementary and sometimes redundant func-
tions, although this type of genetic program differs sub-
stantially between species. For example, there are four
a-defensins in human polymorphonuclear neutrophils
Figure 4. Detection of mRNA Encoding hBD-1 in Normal and CF
(Ganz and Lehrer, 1994, 1995), whereas no a-defensinPulmonary Tissues
protein has been identified inmurine polymorphonuclearAntisense (middle column) and sense (right column) oligonucleo-
neutrophils (Eisenhauer and Lehrer, 1992). The enterictides to the gene encoding hBD-1 were probed to sections of human
defensins exist as a family of up to16 genes in the mouselung tissues and were exposed to photoemulsion for six days. Proxi-
mal (A–C and G–I) and distal noncartilagenous airways (D–F and (Ouellette et al., 1989; Huttner et al., 1994), whereas only
J–L) are shown from normal (top rows [A–F]) and CF (middle rows two human homologs have been identified in human gut
[G–L]) lungs. Representative sections from non-CF (M–O) and CF (Jones and Bevins, 1992, 1993; Mallow et al., 1996).
xenografts (P–R) are also shown (bottom rows). Bright-field (left
While our data suggest a primary role for hBD-1 in lungcolumn) and dark-field (middle column) photomicrographs of the
against some bacterial pathogens, they do not rule outsame region are presented. mRNA encoding hBD-1 was not seen
a role for other antimicrobial substances in the lung.in serial sections hybridized with the antisense probe after treatment
of the section with RNase, confirming the specificity of the assay. The fact that antisense inhibition of hBD-1 does not
Arrowheads indicate epithelium; stars denote submucosal glands. fully prevent microbial killing is consistent with either
Magnification: proximal airway, 83; distal airway and xenografts, incomplete inhibition of hBD-1 or the existence of other
12.53.
bactericidal molecules. Furthermore, other defensins
with complementary functions may play a more signifi-
cant role against fungal, viral, and other bacterial
(i.e., from 50–125 mM). In fact, hBD-1 is partially inacti- pathogens.
vated at the NaCl concentration of non-CF ASF, sug- The question remains as to the contribution of hBD-1
gesting that any perturbation in ASF NaCl concentration inactivation to the pathogenesis of CF. Its role in the
will have a direct effect on hBD-1 function. The most development of disease in extrapulmonary organs such
compelling evidence for the role of hBD-1 in CF lung as liver, pancreas, and the male reproductive tract is
pathogenesis was provided in antisense experiments, not obvious, since infection does not routinely occur at
where specific ablation of hBD-1 function in non-CF these sites. The story in lung is substantially different,
xenografts abolished bactericidal activity in ASF. The where colonization with bacterial pathogens and indices
specificity of this assay was illustrated in control experi- of chronic infection are established in the first four
ments in which mismatches in only 2 of 21 nucleotides months of life in what appears to be an otherwise normal
of the antisense oligonucleotide failed to inhibit hBD-1 pulmonary system (Armstrong et al., 1995, 1996). The
hypothesis that emerges from this work is that a breachactivity.
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in the proximal duct. In the CF sweat gland, Cl absorp-
tion is defective, thus leading to elevated NaCl in sweat
(Quinton, 1983). In extending this model to lung, it will
be important to identify the site(s) of CFTR-independent
Cl secretion into the airway. One possibility is the sub-
mucosal glands, which express high levels of CFTR and
have substantial secretory capacity (Engelhardt et al.,
1992a). Finally, it will be important to reconcile the ele-
vated NaCl in CF ASF with the finding of sodium hyper-
absorption that characterizes the CF defect in polarized
epithelia (Willumsen and Boucher, 1991; Goldman et al.,
1995).
The putative role of hBD-1 in lung pathogenesis of CF
has implications in the development of therapy. This
model supports the rationale for gene therapy in which
reconstitution of CFTR function normalizes the ionic mi-
lieu of the ASF. Indeed, we show in the xenograft model
that as little as z10% gene transfer leads to a diminution
Figure 6. Specific Down-Regulation of RNA for hBD-1 by an Anti-
in ASF NaCl and reconstitution of antimicrobial activity.sense Oligonucleotide
Likewise, pharmacologic approaches for enhancing(A) Airway surface fluid was collected from non-CF xenografts be-
chloride transport through the mutant CFTR or alterna-fore and after the instillation of phosphorothioate oligonucleotides.
tive chloride channels should be useful if ASF NaCl isAntibacterial activity was uniformly present in the ASF from all grafts
before the administration of any oligonucleotide (data not shown). corrected. Pharmacologic administration of b-defensin
Antibacterial broth assays were performed against P. aeruginosa into the airway would be therapeutic only if a salt-insen-
(103 CFU) by incubating the organisms with 30 ml of ASF for 2 hr at sitive peptide were created.
378C, plating serial dilutions of the mixture, and completing colony
counts the following day. Each point shown represents results from
Experimental Proceduresan individual graft.
(B) RT-PCR analysis for RNA encoding hBD-1 and b1-integrin sub-
Recombinant Adenovirusesunit from xenografts treated with phosphorothioate oligonucleo-
The structure, production, and measurement of titer of E1-deletedtides. Four days after the local administration of the oligonucleotide,
viruses that express b-galactosidase (CMV promoter in a sub360grafts were explanted and RNA isolated. RT-PCR was performed
backbone) and CFTR (CMV-enhanced b-actin promoter in a dl7001using hBD-1 or b1-integrin subunit-specific primers, and an aliquot
backbone) have been described previously (Engelhardt et al.,of the reaction mixture blotted to a nitrocellulose membrane and
1993b). The viruses were titred as previously described (Engelhardthybridized with specific probes.
et al., 1993b).
Generation of Bronchial Xenograftsin innate immunity occurs due to the inactivation of
Human bronchial tissues were obtained from explanted or donor
hBD-1 in the high salt environment of the CF ASF, which lungs at the time of lung transplantation, and bronchial xenografts
leads to colonization in the airway with microbial patho- were prepared as previously described (Engelhardt et al., 1992b,
1993a; Goldman et al., 1995). Surface epithelial cells were removedgens and chronic pulmonary inflammation. Other com-
by incubating the bronchus in protease 14 (Sigma), plated in primaryponents of innate immunity and antigen-specific immu-
culture, and maintained for 5–7 days prior to release with trypsin.nity are mobilized without apparent success in clearing
Donor rat tracheas were harvested from CO2-asphyxiated Fisherof bacteria. Major components of the mucus within the
344 rats (200 g), from which the epithelium was denuded by three
airway are derived from debris of the ongoing inflamma- rounds of freeze thawing. These tracheas were ligated to tubing at
tory process, including DNA and cytoskeletal proteins of both ends after seeding of 2 3 106 primary bronchial epithelial cells
in 30 ml of hormonally defined growth medium (Clonetics). Graftsinflammatory cells. Pharmacologic agents that dissipate
were then implanted subcutaneously in the flanks of male nu/nuthe secondary components of mucus, such as DNase
BALB/c mice and maintained for three weeks in vivo to allow forfor DNAand gelsolin for actin, are in fact being evaluated
maturation of a fully differentiated bronchial epithelium. Virus wasfor treatment of the obstructive components of CF lung
instilled into the graft lumen (5 3 1010 pfu/ml, 100 ml) and expelled
disease (Fuchs et al., 1994; Vasconcellos et al., 1994). with air 6 hr later. Samples from three CFlungs (DF508 homozygotes)
One issue not resolved is whether primary defects in and six non-CF lungs were used to generate xenografts for these
studies.mucus biochemistry and rheology also contribute to ob-
structive lung disease and infection.
Transepithelial Potential Difference MeasurementsFurther consideration of this model will require a bet-
Xenografts were analyzed for changes in potential difference (PD)ter understanding of the perturbations in ion and water
in response to perfusion with different solutions before and after
transport that occur at the airway surface in CF. Quanti- gene transfer as described previously (Goldman et al., 1995). In
tative measures of electrolytes in ASF are difficult, al- preparation for these measurements, animals were anesthetized
with intraperitoneally administered ketamine/xylazine (100 ml, 10%though there has been a consistent trend toward ele-
v/v) in phosphate-buffered saline (PBS) (pH 7.4). Agar bridges werevated NaCl in CF in a variety of models, including in vitro
prepared by filling 21-gauge butterfly needles and tubing with 1 Mcultures (Smith et al., 1996), human bronchial xenografts
KCl in 4% agar. The reference bridge was implanted subcutaneously(this study), and native human airway (Gilljam et al.,
in the flank of the mouse while the exploring electrode bridge was
1989; Joris et al., 1993). It is possible the human airway in contact with a reservoir of buffered solution being delivered at a
exhibits a functional similarity to the sweat gland, where constant rate of 2 ml/min by a syringe pump. Each bridge was
connected by a calomel half-cell to a voltmeter. Measurements wereCl is secreted in the lumen in the distal coil and absorbed
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recorded every 10 s by a computer interfaced with the voltmeter. was transferred to fresh LB and incubated for an additional 2–3 hr
at 378C to obtain mid-logarithmic-phase cells. The organisms werePrior to their use, pairs of agar bridges were kept in a common
reservoir of buffered solution and only the electrodes that differed washed with 10 mM sodium phosphate buffer (pH 7.4), and the
concentration of colony-forming units (CFU) per ml21 quantitatedless than 0.2 mV were used for analysis. Each recording measured
voltage as a function of time in response to the sequential perfusion by measuring its absorbance at 620 nm. ASF (30 ml) was mixed with
103 bacterial CFU and incubated for 2 hr at 378C. Serial dilutionsof the following: (i) HEPES phosphate-buffered ringers solution
(HPBR) containing 10 mM HEPES (pH 7.4), 140 mM NaCl, 5 mM were then plated and colony counts completed the following day.
Analyses of airway surface fluid were conducted from at least 12KCl, 1.2 mM MgSO4, 1.2 mM Ca gluconate, 2.4 mM K2HPO4, and
0.4 mM KH2PO4; (ii) HPBR with 100 mM amiloride; (iii) chloride-free individual non-CF and CF xenografts, before and after gene transfer.
Identical studies were also performed on six non-CF xenograftsHPBR (gluconate replaces chloride) with 100 mM amiloride; (iv) chlo-
ride-free HPBR with 100 mM amiloride, 200 mM 8-cpt cAMP, and treated with a recombinant adenovirus expressing b-galactosidase.
100 mM forskolin; and (v) return to HPBR.
Peptide Synthesis
Isolation of the cDNA Encoding hBD-1 A peptide corresponding to the mature form of hBD-1 was synthe-
The cDNA encoding hBD-1 was amplified from primary human bron- sized by the solid phase methodology. The regioselective formation
chial epithelial cell poly(A)1 RNA by 59 and 39 RACE (Frohman et al., of the three disulfide bridges, Cys5–Cys34 (I), Cys12–Cys27 (II), and
1988). The primers used were derived from the nucleotide sequence Cys17–Cys35 (III), was carried out following published procedures
of hBD-1 (Bensch et al., 1995). Amplification products were sub- (Kellenberger et al., 1995). The disulfide bridge I was formed first,
cloned into a Bluescript vector (Stratagene)and sequenced.Multiple followed by the disulfide bridges II and III. The peptide was charac-
clones were analyzed to verify the nucleotide sequence, and a full- terized by mass spectral high performance liquid chromatographic
length cDNA was reconstructed. and capillary zone electrophoretic analyses. A detailed discussion
of the synthesis, purification, and characterization of this molecule
will be published elsewhere.In Situ Analyses
To perform cytochemical analyses, the xenografts were explanted,
embedded in OCT (Tissue-TCK, Miles Inc.), and cryosectioned. Tis- Oligonucleotide Delivery to Xenografts
sue sections (6 mm) were mounted on slides and fixed in 4% para- and Molecular Analysis
formaldehyde in PBS (pH 7.4) for 4 hr. Following fixation, sections Phosphorothioate oligonucleotides consisted of 21-mer analogs to
were dehydrated through graded concentrations of ethanol. Sec- the 59 end of the hBD-1 gene. Mismatches are underlined. Antisense
tions were then desiccated overnight under vacuum and stored 59-CAGAAGGTAGGAAGTTCTCAT-39, nonsense 59-TACAGAGGTG
at 2208C. The following day, sections were treated with 10 mg/ml CTCACTGGGTA-39, mismatched 1 59-CAGAAGGTAGGAAGTTGT
proteinase K for 30 min at 308C, rinsed twice in 0.23 SSC for 30 s CTT-39, and mismatched 2 59-TCTAAGGTAGGGAGTTCTTTG-39
each time, fixed in 4% paraformaldehyde in PBS, rinsed twice in phosphorothioate oligonucleotides were instilled into non-CF xeno-
0.1 M triethanolamine (pH 8.0) for 4 min each time, incubated in grafts at a concentration of 20 mM oligonucleotide in 70 mM phos-
0.25% acetic anhydride for 10 min at room temperature, and then phate buffer (pH 7.4). Any remaining solution was expelled with air
dehydrated through graded concentrations of ethanol. Sections the following day. The ability of ASF to kill bacteria was measured
were again dried under vacuum before prehybridization for 4 hr at before and then three days after oligonucleotide delivery. Antibacte-
548C in 10 mM Tris (pH 8.0), 50% formamide, 2.53 Denhardt’s, 0.6M rial broth assays were performed as previously described. Grafts
NaCl, 1 mM EDTA (pH 8.0), 0.1% SDS, 500 mg/ml tRNA, and 10 mM were harvested four days after oligonucleotide administration and
dithiothreitol (DTT). RNase control sections were treated with 200 total RNA was prepared using RNAzol B (Tel-Test, Inc). RT-PCR
mg/ml RNase A for 1 hr at 378C before the prehybridization step. was performed on 1 mg of template RNA using the Titan RT-PCR
Sections were then hybridized with 5 3 106 cpm/ml 35S antisense system (Boehringer Mannheim) and primer sets specific for hBD-1
or sense probes for 16 hr at 548C. Probes were synthesized with or b1-integrin subunit. Aliquots of the PCR reactions were resolved
the Promega in vitro transcription system using 35S UTP and 35S on a 1% agarose gel, blotted to nitrocellulose, and hybridized to
CTP. cRNA probes for hBD-1 were generated from the T7 and T3 specific 32P random primer-labeled probes. The cDNAfor the human
RNA polymerase promoters of full-length cDNA encoding hBD-1 b1-integrin subunit was kindly provided by Dr. Clayton Buck (The
and were subcloned into BlueScript (Stratagene). Probes for CFTR Wistar Institute, Philadelphia, PA).
were synthesized from the T7 and SP6 RNA polymerase promoters
of a PCR template derived from the cDNA for CFTR. Following Acknowledgments
hybridization, slides were washed in 43 SSC for 20 min (four
changes) at room temperature, RNase (20 mg/ml) for 30 min at 378C, Technical support from Dr. Po-Shun Lee and the contributions of
23 SSC/1 mM DTT at room temperature for 10 min (two changes), the Cell Morphology Core of the Institute for Human Gene Therapy
and finally, three 15 min washes in 0.53 SSC/1 mM DTT at 548C. were greatly appreciated. We are also grateful for technical support
Slides were dehydrated through ethanol and air dried before dipping provided by Suja Rani and Sharon Klepfer of Magainin Pharmaceuti-
in photoemulsion (Kodak). Slides were developed and analyzed by cals. NIDDK and NHLBI of the NIH, the Cystic Fibrosis Foundation,
bright- and dark-field microscopy using a Microphot-FXA Nikon and Genovo Inc. (a company that J. M. W. founded and holds equity
microscope. The efficiency of adenovirus-mediated CFTR gene in) provided financial support.
transfer to xenografts was determined by dividing the number of
positive signals by the total number of cells present in 20 sections Received December 30, 1996; revised January 22, 1997.
derived from multiple blocks of each treated graft. Expression of
hBD-1 was evaluated in xenografts from uninfected samples.
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